Drug Efficacy And Safety ConcernsTirzepatide missed on fibrosis, which limits its use in more advanced NASH patients where resmetirom has shown benefits.
Market ReactionMDGL shares have decreased significantly, which reflects the market's reaction to competing NASH data.
Pricing And Access ChallengesThe $47k per patient per year price tag for Rezdiffra is at the higher end of cost-effectiveness analyses, which could result in commercial barriers.